RBN-2397
RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].
Product Specifications
CAS Number
2381037-82-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rbn-2397.html
Purity
99.82
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1
Molecular Formula
C20H23F6N7O3
Molecular Weight
523.43
Precautions
H302, H315, H319, H335
References & Citations
[1]RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency|[2]Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PARP7
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470226-100 1x 100 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402848-100 1x 100 µL
Fibronectin (Fn-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
